X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA NOVARTIS ELDER PHARMA/
NOVARTIS
 
P/E (TTM) x -0.2 389.6 - View Chart
P/BV x 0.1 19.2 0.5% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 ELDER PHARMA   NOVARTIS
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
NOVARTIS
Mar-16
ELDER PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs380982 38.7%   
Low Rs188556 33.8%   
Sales per share (Unadj.) Rs491.2252.9 194.2%  
Earnings per share (Unadj.) Rs-3.262.1 -5.1%  
Cash flow per share (Unadj.) Rs14.463.3 22.8%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs376.5363.6 103.5%  
Shares outstanding (eoy) m20.5431.96 64.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.0 19.0%   
Avg P/E ratio x-89.312.4 -721.2%  
P/CF ratio (eoy) x19.712.2 162.2%  
Price / Book Value ratio x0.82.1 35.7%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m5,83324,580 23.7%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m2,1791,801 121.0%   
Avg. sales/employee Rs ThNM10,748.9-  
Avg. wages/employee Rs ThNM2,395.2-  
Avg. net profit/employee Rs ThNM2,641.1-  
INCOME DATA
Net Sales Rs m10,0898,083 124.8%  
Other income Rs m257829 30.9%   
Total revenues Rs m10,3468,913 116.1%   
Gross profit Rs m-792234 -338.1%  
Depreciation Rs m36137 984.5%   
Interest Rs m2,7562 153,127.8%   
Profit before tax Rs m-3,6531,025 -356.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m3,7131,696 218.9%   
Tax Rs m125752 16.6%   
Profit after tax Rs m-651,986 -3.3%  
Gross profit margin %-7.82.9 -270.9%  
Effective tax rate %-3.473.4 -4.7%   
Net profit margin %-0.624.6 -2.6%  
BALANCE SHEET DATA
Current assets Rs m9,24012,678 72.9%   
Current liabilities Rs m9,9982,433 410.9%   
Net working cap to sales %-7.5126.7 -5.9%  
Current ratio x0.95.2 17.7%  
Inventory Days Days4633 141.6%  
Debtors Days Days6022 266.5%  
Net fixed assets Rs m10,12469 14,629.6%   
Share capital Rs m206160 128.7%   
"Free" reserves Rs m5,58211,460 48.7%   
Net worth Rs m7,73411,621 66.5%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88214,400 158.9%  
Interest coverage x-0.3570.5 -0.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.6 78.5%   
Return on assets %11.813.8 85.2%  
Return on equity %-0.817.1 -4.9%  
Return on capital %22.323.6 94.6%  
Exports to sales %3.00.7 408.0%   
Imports to sales %0.418.6 2.3%   
Exports (fob) Rs m30760 509.3%   
Imports (cif) Rs m431,503 2.9%   
Fx inflow Rs m307186 164.6%   
Fx outflow Rs m1251,821 6.9%   
Net fx Rs m181-1,635 -11.1%   
CASH FLOW
From Operations Rs m11,7542,531 464.4%  
From Investments Rs m-561-8,270 6.8%  
From Financial Activity Rs m-6,762-386 1,753.1%  
Net Cashflow Rs m4,432-6,125 -72.4%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.5 2.0 375.0%  
FIIs % 16.8 1.6 1,050.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 21.5 167.9%  
Shareholders   16,479 41,647 39.6%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS